Shell Asset Management Co. Raises Stake in The Clorox Company $CLX

Key Points

• Shell Asset Management Co. increased its stake in The Clorox Company by 94.8% during the second quarter, bringing its total holdings to 16,079 shares valued at approximately $1.93 million.
• Clorox exceeded earnings expectations with EPS of $2.87 for the last quarter, beating the estimate of $2.24, and reported revenue of $1.99 billion, surpassing analyst predictions.
• The company declared a quarterly dividend of $1.24 per share, yielding 4.1%, with an ex-dividend date of October 22nd.

Shell Asset Management Co. boosted its position in The Clorox Company (NYSE:CLX - Free Report) by 94.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,079 shares of the company's stock after buying an additional 7,824 shares during the quarter. Shell Asset Management Co.'s holdings in Clorox were worth $1,931,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of CLX. Park Avenue Securities LLC purchased a new stake in Clorox in the first quarter worth approximately $258,000. Courier Capital LLC boosted its stake in Clorox by 11.6% in the first quarter. Courier Capital LLC now owns 2,785 shares of the company's stock worth $410,000 after buying an additional 290 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in Clorox by 25.4% in the first quarter. Farther Finance Advisors LLC now owns 5,872 shares of the company's stock worth $869,000 after buying an additional 1,190 shares in the last quarter. Pallas Capital Advisors LLC purchased a new stake in Clorox in the first quarter worth approximately $647,000. Finally, Wealthcare Advisory Partners LLC boosted its stake in Clorox by 47.8% in the first quarter. Wealthcare Advisory Partners LLC now owns 2,350 shares of the company's stock worth $346,000 after buying an additional 760 shares in the last quarter. Hedge funds and other institutional investors own 78.53% of the company's stock.

Clorox Stock Performance

Shares of CLX stock opened at $119.59 on Thursday. The stock has a fifty day moving average of $122.38 and a 200 day moving average of $129.11. The Clorox Company has a 52 week low of $116.53 and a 52 week high of $171.37. The firm has a market capitalization of $14.63 billion, a price-to-earnings ratio of 18.34, a PEG ratio of 0.98 and a beta of 0.52. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15.

Clorox (NYSE:CLX - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.24 by $0.63. The business had revenue of $1.99 billion during the quarter, compared to analyst estimates of $1.94 billion. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The company's revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.82 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. As a group, research analysts expect that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, November 6th. Shareholders of record on Wednesday, October 22nd will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Wednesday, October 22nd. This represents a $4.96 annualized dividend and a yield of 4.1%. Clorox's dividend payout ratio (DPR) is currently 76.07%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on CLX shares. Weiss Ratings reissued a "hold (c)" rating on shares of Clorox in a research note on Saturday, September 27th. The Goldman Sachs Group dropped their price objective on Clorox from $115.00 to $110.00 and set a "sell" rating for the company in a research note on Wednesday, October 1st. JPMorgan Chase & Co. increased their price objective on Clorox from $133.00 to $135.00 and gave the company a "neutral" rating in a research note on Monday, September 8th. Barclays dropped their price objective on Clorox from $118.00 to $112.00 and set an "underweight" rating for the company in a research note on Tuesday, September 30th. Finally, UBS Group dropped their price objective on Clorox from $134.00 to $128.00 and set a "neutral" rating for the company in a research note on Wednesday. One investment analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat.com, Clorox presently has an average rating of "Reduce" and a consensus price target of $132.92.

Insider Buying and Selling

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of the firm's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the transaction, the chief operating officer owned 54,221 shares of the company's stock, valued at approximately $6,711,475.38. This trade represents a 21.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.57% of the company's stock.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.